A5042967925- Protein Degradation and Inhibitors
- Chromatin Remodeling and Cancer
- Advanced Breast Cancer Therapies
- Multiple Myeloma Research and Treatments
- Neuroblastoma Research and Treatments
- Hedgehog Signaling Pathway Studies
- Epigenetics and DNA Methylation
- Acute Lymphoblastic Leukemia research
- Single-cell and spatial transcriptomics
- Cancer Mechanisms and Therapy
- PARP inhibition in cancer therapy
- Cancer Genomics and Diagnostics
- Genomics and Chromatin Dynamics
- CAR-T cell therapy research
- Radiomics and Machine Learning in Medical Imaging
- Hepatocellular Carcinoma Treatment and Prognosis
- Gene Regulatory Network Analysis
- Glioma Diagnosis and Treatment
- Bioinformatics and Genomic Networks
- Histone Deacetylase Inhibitors Research
- MRI in cancer diagnosis
- Lung Cancer Research Studies
- Light effects on plants
- Coenzyme Q10 studies and effects
- Colorectal Cancer Treatments and Studies
The First Affiliated Hospital, Sun Yat-sen University
2024-2025
Zhongshan Hospital
2024-2025
Fudan University
2024-2025
Sun Yat-sen University
2024-2025
Shanghai Institute of Hematology
2024-2025
St. Jude Children's Research Hospital
2020-2025
The University of Texas MD Anderson Cancer Center
2024
Chinese Academy of Medical Sciences & Peking Union Medical College
2023
Biocom
2018
Virginia Tech
2018
Abstract The variation of transcriptome size across cell types significantly impacts single-cell RNA sequencing (scRNA-seq) data normalization and bulk RNA-seq cellular deconvolution, yet this intrinsic feature is often overlooked. Here we introduce ReDeconv, a computational algorithm that incorporates into scRNA-seq deconvolution. ReDeconv introduces approach, Count based on Linearized Transcriptome Size (CLTS), which corrects differential expressed genes typically misidentified by standard...
Many signaling and other genes known as "hidden" drivers may not be genetically or epigenetically altered differentially expressed at the mRNA protein levels, but, rather, drive a phenotype such tumorigenesis via post-translational modification mechanisms. However, conventional approaches based on genomics differential expression are limited in exposing hidden drivers. Here, we present comprehensive algorithm toolkit NetBID2 (data-driven network-based Bayesian inference of drivers, version...
The oncoprotein and E3 ubiquitin ligase MDM2 ubiquitylates promotes the degradation of circadian clock component PER2.
Augmented reality head-up display (AR-HUD) using diffractive waveguide is a challenging research field. It can drastically reduce the system volume compared with AR-HUD based on freeform mirror. However, one of remaining challenges that affects performance to expand eye-box while maintaining illuminance uniformity. In this paper, one-dimensional pupil expansion optical for presented. The optimization grating parameters scalar diffraction theory and rigorous coupled wave analysis (RCWA)....
Abstract Mutations in Sonic hedgehog (SHH) signaling promote aberrant proliferation and tumor growth. SHH-medulloblastoma (MB) is among the most frequent brain tumors children less than 3 years of age. Although key components SHH pathway are well-known, we hypothesized that new disease-modifying targets SHH-MB might be identified from large-scale bioinformatics systems biology analyses. Using a data-driven approach, built MB-specific interactome. The ATP-binding cassette transporter ABCC4...
Abstract Group3 (G3) medulloblastoma (MB) is one of the deadliest forms disease for which novel treatment desperately needed. Here we evaluate ribociclib, a highly selective CDK4/6 inhibitor, with gemcitabine in mouse and human G3MBs. Ribociclib central nervous system (CNS) penetration was assessed by vivo microdialysis IHC gene expression studies found to be CNS-penetrant. Tumors from mice treated short term oral ribociclib displayed inhibited RB phosphorylation, downregulated E2F target...
<div>Abstract<p>Mutations in Sonic hedgehog (SHH) signaling promote aberrant proliferation and tumor growth. SHH-medulloblastoma (MB) is among the most frequent brain tumors children less than 3 years of age. Although key components SHH pathway are well-known, we hypothesized that new disease-modifying targets SHH-MB might be identified from large-scale bioinformatics systems biology analyses. Using a data-driven approach, built MB-specific interactome. The ATP-binding cassette...
<div>Abstract<p>Mutations in Sonic hedgehog (SHH) signaling promote aberrant proliferation and tumor growth. SHH-medulloblastoma (MB) is among the most frequent brain tumors children less than 3 years of age. Although key components SHH pathway are well-known, we hypothesized that new disease-modifying targets SHH-MB might be identified from large-scale bioinformatics systems biology analyses. Using a data-driven approach, built MB-specific interactome. The ATP-binding cassette...
<p>Supplementary Figure1: ABCC4 amount, regulation and its effect on medulloblastoma patient survival. Supplementary Figure 2: Knockdown of mouse human suppresses SHH signaling. 3: does not influence nuclear cytosolic cAMP but alters PKA-mediated phosphorylation GLI2, Gli3 SUFU. 4: Correlation between level survival neuroblastoma, adrenocortical carcinoma, liver hepatocellular breast cancer.</p>
<p>Supplementary Figure1: ABCC4 amount, regulation and its effect on medulloblastoma patient survival. Supplementary Figure 2: Knockdown of mouse human suppresses SHH signaling. 3: does not influence nuclear cytosolic cAMP but alters PKA-mediated phosphorylation GLI2, Gli3 SUFU. 4: Correlation between level survival neuroblastoma, adrenocortical carcinoma, liver hepatocellular breast cancer.</p>
Supplementary Figure from Combination of Ribociclib and Gemcitabine for the Treatment Medulloblastoma
Supplementary Data from Combination of Ribociclib and Gemcitabine for the Treatment Medulloblastoma
<p>Supplementary Methods, Figures S1-S9 and Tables S3, S5-S7</p>
Supplementary Data from Combination of Ribociclib and Gemcitabine for the Treatment Medulloblastoma